Optimising Antibody Drug Conjugate Development: The Role of RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay in Enhanced Data Collection
Grant Harradence, Bioassay Manager at Abzena, coordinates cytotoxicity and functional assays to support drug discovery. In this short video, Grant explains that his team deploys assays strategically at different stages, using the CellTiter-Glo® Cell Viability Assay for initial ADC screening to identify the most promising candidates before moving to the RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay for deeper insights into each bioconjugate’s mode of action and kinetics. Guided by client feedback, Grant discusses the shift from traditional endpoint assays to real-time data collection with the RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay, which enables his team to gather continuous, comprehensive information essential for optimising ADC development.
Grant further highlights the advantages of the RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay, emphasising its ease of integration and minimal need for optimisation, which allows his team to manage multiple projects concurrently. This efficiency lets them focus more on data analysis, accelerating ADC research. He underscores the transformative potential of ADCs in cancer therapeutics and explains how, through these innovations, Abzena’s work is advancing targeted cancer treatments in impactful ways.
